Search Results
You are looking at 1 - 2 of 2 items for
- Author: JC Fruchart x
- Refine by access: All content x
Search for other papers by P Delerive in
Google Scholar
PubMed
Search for other papers by JC Fruchart in
Google Scholar
PubMed
Search for other papers by B Staels in
Google Scholar
PubMed
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear receptor superfamily. PPARalpha is highly expressed in liver, skeletal muscle, kidney, heart and the vascular wall. PPARgamma is predominantly detected in adipose tissue, intestine and macrophages. PPARs are activated by fatty-acid derivatives and pharmacological agents such as fibrates and glitazones which are specific for PPARalpha and PPARgamma respectively. PPARs regulate lipid and lipoprotein metabolism, glucose homeostasis, cell proliferation and differentiation, and apoptosis. PPARalpha controls intra- and extracellular lipid metabolisms whereas PPARgamma triggers adipocyte differentiation and promotes lipid storage. In addition, PPARs also modulate the inflammatory response. PPAR activators have been shown to exert anti-inflammatory activities in various cell types by inhibiting the expression of proinflammatory genes such as cytokines, metalloproteases and acute-phase proteins. PPARs negatively regulate the transcription of inflammatory response genes by antagonizing the AP-1, nuclear factor-kappaB (NF-kappaB), signal transducer and activator of transcription and nuclear factor of activated T-cells signalling pathways and by stimulating the catabolism of proinflammatory eicosanoids. These recent findings indicate a modulatory role for PPARs in inflammation with potential therapeutical applications in chronic inflammatory diseases.
Search for other papers by M Lefebvre in
Google Scholar
PubMed
Search for other papers by B Paulweber in
Google Scholar
PubMed
Search for other papers by L Fajas in
Google Scholar
PubMed
Search for other papers by J Woods in
Google Scholar
PubMed
Search for other papers by C McCrary in
Google Scholar
PubMed
Search for other papers by JF Colombel in
Google Scholar
PubMed
Search for other papers by J Najib in
Google Scholar
PubMed
Search for other papers by JC Fruchart in
Google Scholar
PubMed
Search for other papers by C Datz in
Google Scholar
PubMed
Search for other papers by H Vidal in
Google Scholar
PubMed
Search for other papers by P Desreumaux in
Google Scholar
PubMed
Search for other papers by J Auwerx in
Google Scholar
PubMed
Peroxisome proliferator-activated receptor gamma (PPARgamma), a fatty acid-activated nuclear receptor, is implicated in adipocyte differentiation and insulin sensitisation. In view of the association of dietary fat intake and bowel disease, the expression of PPARgamma in rodent and human intestine was studied. Expression of PPARgamma mRNA was examined by Northern blot hybridisation, RNase protection, and/or competitive RT-PCR assays, whereas PPARgamma protein levels were evaluated by immunoblotting and immunohistochemistry. PPARgamma mRNA and protein were abundantly expressed in colon relative to the small intestine both in rodents and in man. Interestingly, expression of PPARgamma was primarily localised in the more differentiated epithelial cells in the colon. The level of expression of PPARgamma in colon was similar to the levels seen in adipose tissue. Expression of PPARgamma increased from proximal to distal segments of the colon in man. In Caco-2 and HT-29 human adenocarcinoma cells, PPARgamma expression increased upon differentiation, consistent with PPARgamma being associated with a differentiated epithelial phenotype. High-level expression of PPARgamma was observed in the colon, but not in the small intestine, suggesting a potential role of this nuclear receptor in the colon.
